Evidence map›Paper›PMID 24359708›Full record

ArticleBioorganic & medicinal chemistry2014

Methyl-substituted conformationally constrained rexinoid agonists for the retinoid X receptors demonstrate improved efficacy for cancer therapy and prevention.

Anil Desphande, Gang Xia, LeeAnn J Boerma, Kimberly K Vines, Venkatram R Atigadda, Susan Lobo-Ruppert, Clinton J Grubbs, Fariba L Moeinpour, Craig D Smith, Konstantin Christov and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Increased Molecular Flexibility Widens the Gap betweenACS medicinal chemistry letters · 2022
    Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Anil DesphandeDepartment of Chemistry, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Gang XiaDepartment of Chemistry, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
LeeAnn J BoermaDepartment of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Kimberly K VinesDepartment of Chemistry, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Venkatram R AtigaddaDepartment of Chemistry, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Susan Lobo-RuppertDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Clinton J GrubbsDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Fariba L MoeinpourDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Craig D SmithDepartment of Vision Sciences, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Konstantin ChristovDepartment of Surgical Oncology, University of Illinois, Chicago, IL 60612, USA.
Wayne J BrouilletteDepartment of Chemistry, University of Alabama at Birmingham, Birmingham, AL 35294, USA. Electronic address: wbrou@uab.edu.
Donald D MuccioDepartment of Chemistry, University of Alabama at Birmingham, Birmingham, AL 35294, USA. Electronic address: muccio@uab.edu.
University of Alabama at Birmingham · USUniversity of Illinois Chicago · US

Funding

UAB Rexinoids for Breast Cancer PreventionP50CA089019 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GRIZZLE, WILLIAM E. · 2000 to 2011
$26.0M
NCI NIH HHS 2P50 CA089019NCI NIH HHS P50 CA089019
6 · The paper itself

Abstract

(2E,4E,6Z,8Z)-8-(3',4'-Dihydro-1'(2H)-naphthalen-1'-ylidene)-3,7-dimethyl-2,3,6-octatrienoinic acid, 9cUAB30, is a selective rexinoid for the retinoid X nuclear receptors (RXR). 9cUAB30 displays substantial chemopreventive capacity with little toxicity and is being translated to the clinic as a novel cancer prevention agent. To improve on the potency of 9cUAB30, we synthesized 4-methyl analogs of 9cUAB30, which introduced chirality at the 4-position of the tetralone ring. The syntheses and biological evaluations of the racemic homolog and enantiomers are reported. We demonstrate that the S-enantiomer is the most potent and least toxic even though these enantiomers bind in a similar conformation in the ligand binding domain of RXR.

Indexed as

HumansKruppel-Like Factor 4LigandsMolecular ConformationNeoplasmsRetinoidsRetinoid X ReceptorsKLF4 protein, humanKlf4 protein, ratKruppel-Like Factor 4LigandsRetinoidsRetinoid X Receptors2-iodoxybenzoic acidCancer preventionConformationally constrained retinoidsDMEMDulbecco’s modified Eagle mediumERestrogen receptorglucocorticoid receptor interacting protein-1GRIP-1hexamethylphosphoramideHMPAIBXKLF4Kruppel-like factor 4LBDLBPligand binding domainligand binding pocketLigand–protein crystal structuresliver X receptorsLXRsNRnuclear receptorPDBprotein data bankRARARrat kidney epithelialretinoic acidretinoic acid receptorretinoid X receptorRexinoidsRKERMSDroot mean square deviationRXRSCCsquamous cell carcinomatetrahydrofuranTGTHFthin layer chromatographyTLCtriglycerides

Identifiers

PMID24359708
PMCPMC4387854
OpenAlexW1964903490

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.